iBio (IBIO) 10-K2024 FY Annual report

Filed: 20 Sep 24, 4:14pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: absence, adolescent, adult, alongside, annexed, Arcadia, AstraBio, AstralBio, ATM, balloon, beta, Biohaven, bone, Brookline, Brownian, bundle, buyback, calorie, cardiometabolic, Carlo, cessation, Chardan, Clawback, cleaved, computerized, conditionally, consequential, cyber, deeply, density, deploy, deployed, deploying, door, doubled, easily, EHS, eighty, entail, entailed, enzyme, epidemic, excise, extinguishment, family, fat, fitting, Forest, frailty, Fundamental, fundraising, Geometric, grassi, guideline, hyperplasia, hypertrophy, inappropriate, incidental, incretin, indemnify, Instruction, interacting, Jericho, Journal, Lake, Lastly, leakage, leukemia, linker, lock, Loeb, malware, metabolic, metabolism, metric, misapplication, misrepresentation, Monte, Motion, muscle, myostatin, negligence, NIST, nominal, NY, obesity, older, Otsuka, overseeing, overweight, PFI, pharmacologic, Pharmacological, PIPE, placement, prevalent, proactively, quadrupled, reassessed, rebound, recurrence, Releveled, representation, reproduce, revocation, Rock, Scholar, ShieldTx, signatory, signature, Simplification, simulation, sixty, skeletal, solicitation, sophisticated, sophistication, stewardship, Street, Subtopic, Suite, superfamily, tackle, Tail, technique, telecommunication, TGF, TGFb, today, transmit, unfit, unsalable, unusual, Wall, warranty, West, wire, withdrew

Removed: affirmative, aid, Carol, classify, CohnReznick, connective, consistency, consumer, correlation, corroborated, CPI, disorder, doubtful, endostatin, FastPharming, formation, Foundation, hedging, hourly, iBioLaunch, idiopathic, inflammatory, IPF, LicKM, LLP, newer, overwhelming, parenchymal, pathological, Paycheck, pertinent, PPP, predominant, professional, Professor, prohibition, pulmonary, recognizing, relief, remodeling, repaying, River, SBA, scar, scleroderma, separated, skin, SSc, standalone, travel, TTA, unadjusted, unchecked, underwriter

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

IBIO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of iBio, Inc. (the Company) on Form 10-K for the fiscal year ended June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Martin Brenner, Chief Executive Officer and Chief Scientific Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:


	1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


September 20, 2024	/s/ Martin Brenner
	Martin Brenner
	Chief Executive Officer and Chief Scientific Officer
	(Principal Executive Officer)

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to iBio, Inc. and will be furnished to the Securities and Exchange Commission or its staff upon request.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.